Baxter International (BAX) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

Baxter and Hillrom Integration - Baxter is integrating Hillrom and evaluating revenue growth opportunities in a $40 billion+ total addressable market (TAM) with a 5%+ weighted average market growth rate (WAMGR)[5] - Baxter expects to deliver approximately $250 million of annual pre-tax cost synergies by the end of 2024 through optimizing organizational design, simplifying processes, vendor contracting, and consolidating operations and facilities[5, 30] - Baxter anticipates low double-digit accretion to adjusted earnings beginning in 2022 and expanding thereafter, with a high-single digit Return on Invested Capital (ROIC) expected by 2026[5] Financial Performance and Strategy - In FY 2020, the combined revenue geography was 47% in the U S and 53% outside the U S[8] - Baxter announced a quarterly dividend of $0.28 per share, reflecting a strong financial position and commitment to returning value to investors[31] - Baxter plans to moderate share repurchases in the near term to focus on deleveraging[31] Innovation and Product Development - Baxter is launching new products like the Novum IQ Suite, Premix Injectables, PanOptic & MacroView Plus, and Prismax 2 to meet the needs of patients and providers[28] - Baxter is investing $275 million in underserved communities[32] Corporate Responsibility - Baxter aims to achieve carbon neutrality for direct operations by 2040[32]